Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | PPARA | Q07869 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | PRKACA | P17612 | 1/20 | 0.62 |
| ▸ | GSK3A | P49840 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339004 | 0.91 | MMP13 (0.67) | MMP13CYP3A4CYP1A2TSHRBLM | |
| SCHEMBL5335114 | 0.90 | MMP13 (0.66) | MMP13CYP3A4CYP1A2TSHRBLM | |
| SCHEMBL5338148 | 0.87 | L3MBTL1 (0.74) | CYP3A4CYP1A2TSHRBLMHPGD | |
| SCHEMBL5335138 | 0.86 | CYP1A2 (0.66) | MMP13CYP3A4CYP1A2TSHRBLM | |
| SCHEMBL5335143 | 0.86 | CYP1A2 (0.66) | MMP13CYP3A4CYP1A2TSHRBLM | |
| SCHEMBL18641776 | 0.86 | HPGD (0.74) | MMP13HPGDLMNAPPARAKDM4E | |
| SCHEMBL29617703 | 0.86 | HPGD (0.74) | MMP13HPGDLMNAPPARAKDM4E | |
| SCHEMBL5334043 | 0.86 | CYP1A2 (0.65) | CYP3A4CYP1A2TSHRBLMCYP2C19 | |
| SCHEMBL31061610 | 0.85 | MMP13 (1.00) | MMP13CYP3A4HPGDLMNAKDM4E | |
| SCHEMBL9416645 | 0.85 | MMP13 (0.94) | MMP13CYP3A4HPGDLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | claimed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | claimed |
| EP-1362028-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | claimed |
| WO-2002064547-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | disclosed |
| EP-1361873-A4 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1531904-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004007024-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006912-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1361873-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362028-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064547-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP3 | MMP13 1/4885CYP3A4 354/4885CYP1A2 857/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | MMP13 1/4885CYP3A4 1825/4885CYP1A2 2997/4885 |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | MMP13 1/4885CYP3A4 824/4885CYP1A2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.